Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2019, Article ID 7604939, 7 pages
https://doi.org/10.1155/2019/7604939
Research Article

Frequency of Hepatobiliary Manifestations and Concomitant Liver Disease in Inflammatory Bowel Disease Patients

1Department of Life Sciences, Universidade do Estado da Bahia, Rua Silveira Martins 2555, Cabula 41150-000, Salvador, Bahia, Brazil
2Hospital Geral Roberto Santos (HGRS), Rua Direta do Saboeiro s/n, Cabula - CEP: 41180-780, Salvador, Bahia, Brazil
3Gastroenterology Unit, University Hospital Professor Edgard Santos, Universidade Federal da Bahia, Rua Augusto Viana sn/28 andar, Canela 40110-060, Salvador, Bahia, Brazil
4Departamento Ciência da Nutrição, Escola de Nutrição, Universidade Federal da Bahia, Avenida Araújo Pinho, 32, Canela 40110-150, Salvador, Bahia, Brazil

Correspondence should be addressed to Genoile O. Santana; rb.moc.lou@elioneg

Received 5 September 2018; Accepted 15 January 2019; Published 31 January 2019

Academic Editor: Hon W. Koon

Copyright © 2019 Juliana Silva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Cosnes, C. Gowerrousseau, P. Seksik, and A. Cortot, “Epidemiology and natural history of inflammatory bowel diseases,” Gastroenterology, vol. 140, no. 6, pp. 1785–1794, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. J. Basso, M. T. Fonseca, G. Bonfá et al., “Association among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel disease,” Brazilian Journal of Medical and Biological Research, vol. 47, no. 9, pp. 727–737, 2014. View at Publisher · View at Google Scholar
  3. E. Gizard, A. C. Ford, J.-P. Bronowicki, and L. Peyrin-Biroulet, “Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease,” Alimentary Pharmacology & Therapeutics, vol. 40, no. 1, pp. 3–15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Rojas-Feria, M. Castro, E. Suárez, J. Ampuero, and M. Romero-Gómez, “Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver,” World Journal of Gastroenterology, vol. 19, no. 42, pp. 7327–7340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Saich and R. Chapman, “Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 14, no. 3, pp. 331–337, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Restellini, O. Chazouillères, and J.-L. Frossard, “Hepatic manifestations of inflammatory bowel diseases,” Liver International, vol. 37, no. 4, pp. 475–489, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. J. P. Gisbert, M. Chaparro, and M. Esteve, “Review article: Prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease,” Alimentary Pharmacology & Therapeutics, vol. 33, no. 6, pp. 619–633, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Satsangi, M. S. Silverberg, S. Vermeire, and J.-F. Colombel, “The montreal classification of inflammatory bowel disease: Controversies, consensus, and implications,” Gut, vol. 55, no. 6, pp. 749–753, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Zippi, C. Corrado, R. Pica et al., “Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients,” World Journal of Gastroenterology, vol. 20, no. 46, pp. 17463–17467, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Lakatos, T. Pandur, G. David et al., “Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: Results of a 25-year follow-up study,” World Journal of Gastroenterology, vol. 9, no. 10, pp. 2300–2307, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. A. B. De Vries, M. Janse, H. Blokzijl, and R. K. Weersma, “Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis,” World Journal of Gastroenterology, vol. 21, no. 6, pp. 1956–1971, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Wang and R. W. Leong, “Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: A review of the literature,” World Journal of Gastroenterology, vol. 20, no. 27, pp. 8783–8789, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Nakazawa, I. Naitoh, K. Hayashi et al., “Inflammatory bowel disease of primary sclerosing cholangitis: A distinct entity?” World Journal of Gastroenterology, vol. 20, no. 12, pp. 3245–3254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. M. M. H. Claessen, M. W. M. D. Lutgens, H. R. Van Buuren et al., “More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis,” Inflammatory Bowel Diseases, vol. 15, no. 9, pp. 1331–1336, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. H. H. Rasmussen, J. F. Fallingborg, P. B. Mortensen et al., “Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with crohn’s disease,” Scandinavian Journal of Gastroenterology, vol. 32, no. 6, pp. 604–610, 2009. View at Publisher · View at Google Scholar
  16. C. N. Bernstein, J. F. Blanchard, P. Rawsthorne, and N. Yu, “The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study,” American Journal of Gastroenterology, vol. 96, no. 4, pp. 1116–1122, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Bambha, W. R. Kim, J. Talwalkar et al., “Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community,” Gastroenterology, vol. 125, no. 5, pp. 1364–1369, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Perdigoto, H. A. Carpenter, and A. J. Czaja, “Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis,” Journal of Hepatology, vol. 14, no. 2-3, pp. 325–331, 1992. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Matteoni, L. Boente, and D. Soares, “Nonalcoholic fatty hepatic disease: Relevance of the diagnosis on abdominal ultrasound,” Gazeta Médica da Bahia, vol. 81, no. 1, pp. 7–9, 2011. View at Google Scholar
  20. J. M. L. Parente, C. S. R. Coy, V. Campelo et al., “Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil,” World Journal of Gastroenterology, vol. 21, no. 4, pp. 1197–1206, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. J.-B. Chevaux, M.-A. Bigard, M. Bensenane et al., “Inflammatory bowel disease and hepatitis B and C,” Gastroentérologie Clinique et Biologique, vol. 33, no. 12, pp. 1082–1093, 2009. View at Publisher · View at Google Scholar · View at Scopus